Journal of Neural Transmission

, Volume 106, Issue 9, pp 925–929

An overnight switch to ropinirole therapy in patients with Parkinson's disease

Authors

  • M. Canesi
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • A. Antonini
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • C. B. Mariani
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • S. Tesei
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • A. L. Zecchinelli
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • M. Barichella
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • G. Pezzoli
    • Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
Short Communication

DOI: 10.1007/s007020050212

Cite this article as:
Canesi, M., Antonini, A., Mariani, C. et al. J Neural Transm (1999) 106: 925. doi:10.1007/s007020050212

Summary.

Patients with Parkinson's disease (n = 68) switched from per-golide or bromocriptine to ropinirole overnight (dose equivalence ratios – 1 : 6 and 10 : 6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine–ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.

Keywords: RopinirolepergolidebromocriptineParkinson's disease.

Copyright information

© Springer-Verlag Wien 1999